Rallybio (RLYB)
(Real Time Quote from BATS)
$1.61 USD
+0.02 (1.26%)
Updated May 21, 2024 03:05 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Rallybio Corporation [RLYB]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
FNAIT Partnership With JJ Highlights RLYB212 Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
RLYB212 Phase 2 Initiates 2H24; 2023 Financials; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
FNAIT Study On Track For 2H24 Start Following EMA Input
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Pipeline Prioritization Lengthens Cash Runway; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
A Catalyst-Rich Year; Focus Remains on RLYB212 and RLYB116; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
RLYB116 Phase 1 Data Drive Once-Weekly Subcutaneous Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Encouraging RLYB212 Preliminary Phase 1 Multiple Dose Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Phase 1 MAD RLYB212 Wraps Up - Moving Towards Phase 2 And RLYB116 Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Two YE23 Catalysts Approaching; 3Q23 Financials; Modulating PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Complement Inhibition In Focus Soon With RLYB116 Updates In 4Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
RLYB116 Phase 1 SAD Data Underscores Clinical Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Two Data Catalysts in 4Q23; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M